'Migraine Experience' Debuts Excedrin Advertising By Glaxo/Novartis JV
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Excedrin Migraine’s multi-channel campaign, the first major promotion for the brand since moving into the Glaxo/Novartis JV, incorporates "augmented reality" technology for a window into the struggles of migraine sufferers.
You may also be interested in...
Relief For Excedrin Migraine, Green For Package
Approved changes are for primary display panel on immediate container and outer carton for total of eight packages, from 24- to 300-count, and include making the brand name Excedrin Migraine Relief.
Novartis OTC Plant Troubled By Quality Failures A Year After Shutdown
FDA recorded nine observations – many of them repeats from 2011 and 2012 – on a form 483 during its early 2013 visit to Novartis Consumer Health’s facility in Lincoln, Nebraska. The observations cited inadequate consumer complaint handling and container closure stability testing.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.